Valuation: Glaukos Corporation

Market Cap 10.9B 9.34B 8.74B 8B 15.01B 1,043B 15.21B 103B 40.25B 524B 40.93B 40.04B 1,733B P/E 2026 *
-229x
P/E 2027 * 629x
Enterprise Value 10.73B 9.19B 8.6B 7.87B 14.77B 1,026B 14.96B 102B 39.61B 516B 40.27B 39.4B 1,705B EV / Sales 2026 *
15.5x
EV / Sales 2027 * 12.6x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 week+0.20%
Current month+10.90%
1 month+20.95%
3 months+53.78%
6 months+53.73%
Current year+63.75%
1 week 175.04
Extreme 175.04
191.62
1 month 145.78
Extreme 145.7759
191.62
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 2000-12-31
Director of Finance/CFO 56 2022-03-31
President 50 2022-03-31
Director TitleAgeSince
Chairman 65 2021-12-30
Director/Board Member 71 2014-06-30
Director/Board Member 57 2014-06-30
Date Insider Type Main position Quantity % Market Cap.
8/19/26 Fiscal year

Director

7,500 0.0131%
8/11/26 Fiscal year

Chairperson

180,000 0.3139%
8/7/26 Fiscal year

Chief Financial Officer

60,000 0.1046%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.20%+96.38%+148.34% 10.9B
+0.53%-2.88%-16.43%+19.59% 126B
-0.37%-2.42%-22.67%+0.75% 12.26B
-4.90%-8.39%-52.04%-69.44% 4.14B
-0.43%-1.43%-24.31%+48.56% 2.69B
+1.78%+9.21%-35.03%-71.13% 1.8B
-1.13%-0.43%-23.65%-12.13% 1.66B
-3.68%-3.53%-35.52%-37.74% 1.61B
-0.46%0.00%-17.11%-53.36% 1.5B
Average -0.96%-0.54%-14.49%-2.95% 18.1B
Weighted average by Cap. +0.22%-2.50%-10.86%+22.44%

Financials

2026 *2027 *
Net sales 691M 592M 554M 507M 951M 66.1B 964M 6.54B 2.55B 33.21B 2.59B 2.54B 110B 845M 723M 677M 620M 1.16B 80.81B 1.18B 8B 3.12B 40.59B 3.17B 3.1B 134B
Net income -51.88M -44.44M -41.58M -38.07M -71.44M -4.96B -72.38M -491M -192M -2.49B -195M -191M -8.25B 18.93M 16.21M 15.17M 13.89M 26.06M 1.81B 26.4M 179M 69.89M 910M 71.07M 69.52M 3.01B
Net Debt -175M -150M -140M -128M -241M -16.73B -244M -1.66B -646M -8.41B -657M -642M -27.8B -273M -234M -219M -200M -376M -26.1B -381M -2.58B -1.01B -13.11B -1.02B -1B -43.37B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
26-08-21 US$184.89 0.00% 440,096
26-08-20 US$184.89 -2.46% 791,869
26-08-19 US$189.55 +2.93% 505,426
26-08-18 US$184.15 -0.79% 625,626
26-08-17 US$185.62 +0.59% 734,774
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
184.89USD
Average target price
197.15USD
Spread / Average Target
+6.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock